Search research articles
Contact Us
Filters
Showing results (141-150 of 188) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
European Journal of Haematology
|
April 21, 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study
Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, et al.
Blood
|
November 3, 2009
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M Lokhorst, Bronno van der Holt, Sonja Zweegman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Antonio Palumbo, Francesca Gay, Federica Cavallo, et al.
European Journal of Haematology
|
May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Philippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2025
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Plos Genetics
|
October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
Isabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
European Journal of Haematology
|
February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Leukemia & Lymphoma
|
January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Haematologica
|
August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 188) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
European Journal of Haematology
|
April 21, 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study
Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, et al.
Blood
|
November 3, 2009
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M Lokhorst, Bronno van der Holt, Sonja Zweegman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Antonio Palumbo, Francesca Gay, Federica Cavallo, et al.
European Journal of Haematology
|
May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Philippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2025
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Plos Genetics
|
October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
Isabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
European Journal of Haematology
|
February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Leukemia & Lymphoma
|
January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Haematologica
|
August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Page
of 19